Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Dementia

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

An update on the cause and treatment of sleep disturbance in children and adolescents with autism spectrum disorder.

Yeungnam University journal of medicine·2021

Same journal

Understanding insomnia as systemic disease.

Yeungnam University journal of medicine·2021

Same journal

Understanding sleep and sleep disturbances in autism spectrum disorder, and management of insomnia: an update.

Yeungnam University journal of medicine·2021

Same journal

An update on immunotherapy with PD-1 and PD-L1 blockade.

Yeungnam University journal of medicine·2021

Same journal

Anesthetic management during whole-lung lavage using lung ultrasound in a patient with pulmonary alveolar proteinosis: a case report.

Yeungnam University journal of medicine·2021

Same journal

Treatment decision for cancer patients with fever during the coronavirus disease 2019 (COVID-19) pandemic.

Yeungnam University journal of medicine·2021

Search research articles

Related Experiment Video

Updated: Jan 5, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Beta-amyloid imaging in dementia.

Kyung Ah Chun¹

¹Department of Nuclear Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Yeungnam University Journal of Medicine

|October 18, 2019

Summary

This summary is machine-generated.

Alzheimer's disease (AD) diagnosis is improved by amyloid-beta (Aβ) imaging. This technique visualizes Aβ plaques, aiding in predicting disease progression and developing targeted therapies.

Keywords:

Alzheimer’s disease Amyloid-beta Positron emission tomography

More Related Videos

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jan 5, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Area of Science:

Neurology
Neuroimaging
Biomarkers

Background:

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques.
Aβ accumulation is a key event leading to neurofibrillary degeneration and dementia.

Purpose of the Study:

To highlight the role of Aβ burden as a predictive biomarker in AD.
To discuss the utility of positron emission tomography (PET) imaging in visualizing and quantifying Aβ deposition.

Main Methods:

Utilizing positron emission tomography (PET) with amyloid-binding ligands.
Examples of PET tracers include 11C-Pittsburgh Compound B and 18F-labeled tracers (florbetaben, florbetapir, flutemetamol).

Main Results:

Aβ imaging demonstrates high sensitivity in detecting AD pathology.
Aβ burden assessed by neuroimaging is an excellent predictive biomarker for AD.

Conclusions:

Amyloid-beta imaging is a valuable tool for visualizing and quantifying Aβ in living subjects.
Aβ imaging can predict the progression from mild cognitive impairment to AD.
This technique supports the development of disease-specific therapies for Alzheimer's disease.